Observation of clinical efficacy of S-1 combined with oxaliplatin in neoadjuvant chemotherapy for local advanced gastric carcinoma

Abstract

Objective To observe the clinical efficacy of S-1 plus oxaliplatin (SOX) in neoadjuvant chemotherapy for patients with local advanced gastric carcinoma. Methods Clinicopathological data of 68 patients with local advanced gastric cancer were retrospectively analyzed and enrolled as treatment group.All the patients in the treatment group achieved 3-4 cycles chemotherapy of SOX regimen preoperatively.Outcomes of tumor remission after neoadjuvant chemotherapy were evaluated according to RECISI1.1 criteria.Meanwhile, 70 patients who underwent operation directly after pathological diagnosis of local advanced gastric cancer during the same period were recruited as control group.Resection rate, R0 resection rate, postoperative complications rate and postoperative progression free survival(PPFS) time were compared between the two groups. Results In the treatment group, after neoadjuvant chemotherapy, 4 cases(5.9%) achieved complete remission, 36 cases(52.9%) achieved partial remission.Meanwhile, the numbers of cases with stable disease and progressive disease were 15 cases(22.1%) and 13 cases(19.1%) respectively.The objective remission rate and disease control rate in the treatment group were 58.8% and 80.9% respectively.The tumor resection rate, R0 resection rate, postoperative complications rate in the treatment group were 92.6%, 85.3% and 14.7% respectively.The R0 resection rate in the treatment group was higher than that in the control group, the difference was statistically significant(χ2=8.042, P 0.05). The median time of PPFS in the treatment group and the control group was 36 months and 30 months respectively, there was statistically significant difference in PPFS between the two groups(χ2=4.049, P<0.05). Conclusion The neoadjuvant chemotherapy of S-1 plus oxaliplatin for local advanced gastric carcinoma has satisfactory short-term effect and can also improve PPFS.However, further investigation is required to observe the effect of this neoadjuvant chemotherapy regimen on postoperative overall survival. Key words: Gastric Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Oxaliplatin